Form 4: Verve Therapeutics CEO Sekar Kathiresan Reports Stock Option Exercise and Share Transactions

CEO Sekar Kathiresan reports exercising stock options and acquiring shares of Verve Therapeutics, Inc.

Summary

• Sekar Kathiresan, CEO of Verve Therapeutics, reported transactions involving the company's common stock and stock options.
• On June 28, 2024, Kathiresan exercised stock options to acquire 30,000 shares at a price of $2.87 per share.
• Following the reported transactions, Kathiresan directly owns 351,128 shares of common stock.
• Kathiresan also indirectly owns 240,997 shares through the Kathiresan Family 2021 Irrevocable Trust and 80,997 shares through the Sekar Kathiresan 2021 Irrevocable Trust.
• Kathiresan also indirectly owns stock options to buy 160,000 shares through the Sekar Kathiresan 2022 Annuity Trust and 200,000 shares through the Sekar Kathiresan 2023 Annuity Trust.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reflecting standard insider trading activity. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• The reported transactions are typical for executives who receive stock options as part of their compensation packages.
• Comparable companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also have similar insider transaction reporting requirements.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the CEO's stock ownership and trading activity.
• The transactions may have a minor impact on the stock price, depending on market perception.

Key Dates